Oxford GlycoSciences (OGS) spent 2000 developing its first drug candidate, Vevesca, and filing mor...
Oxford GlycoSciences (OGS) spent 2000 developing its first drug candidate, Vevesca, and filing more than 1,500 patents on proteins in a "land grab". Revenue from Vevesca, a drug for the treatment of the rare metabolic disorder Gaucher's disease, is not expected for another year. OGS will lodge the drug for approval in the summer. Net operating costs rose by 36% to £28.9m in 2000 and a further rise, although a smaller percentage, is expected this year as the R&D program is stepped up.
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
